Is colesevelam indicated for a patient with elevated liver enzymes, hyperchloremia, impaired renal function, and albuminuria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Colesevelam Indications

Colesevelam is FDA-approved for lowering LDL cholesterol in adults with primary hyperlipidemia, improving glycemic control in adults with type 2 diabetes, and reducing LDL-C in pediatric patients (ages 10-17) with heterozygous familial hypercholesterolemia. 1

FDA-Approved Indications

Colesevelam hydrochloride is indicated as an adjunct to diet and exercise for:

  • Primary Hyperlipidemia: Reducing elevated LDL-C in adults, either as monotherapy or combined with statins 2
  • Type 2 Diabetes: Improving glycemic control in adults (unique among lipid-lowering agents as the only FDA-approved drug for both LDL-C and glucose lowering) 2
  • Pediatric Heterozygous Familial Hypercholesterolemia: Lowering LDL-C in boys and post-menarchal girls aged 10-17 years who cannot reach target levels despite adequate diet and lifestyle modifications 1

Efficacy Profile

  • Monotherapy: Reduces LDL-C by 15-22% 2
  • Combination with statins: Provides an additional 10-16% LDL-C reduction 2
  • Glycemic control: Reduces HbA1c by approximately 0.5% (4 mmol/mol) in patients with type 2 diabetes 3

Critical Contraindications for Your Patient

Colesevelam is contraindicated in patients with triglycerides >500 mg/dL, history of hypertriglyceridemia-induced pancreatitis, or bowel obstruction. 1

Specific Concerns with Your Patient's Profile:

Elevated liver enzymes: While colesevelam is non-systemic and not metabolized by the liver, post-marketing reports document increased transaminases 1. The FDA label notes this as a laboratory abnormality to monitor 1. However, colesevelam may actually be safer than systemic agents in hepatic dysfunction since it acts only in the GI tract 4.

Impaired renal function: Colesevelam is non-systemic and not renally cleared, making it theoretically safe in renal impairment 4. Unlike systemic lipid-lowering agents, no dose adjustment is required for renal dysfunction 5. This is a potential advantage over statins and other systemically absorbed agents.

Hyperchloremia: This is not listed as a contraindication or precaution in the FDA label 1. Colesevelam does not directly affect electrolyte balance.

Albuminuria: Not a contraindication. The drug's non-systemic nature means it doesn't undergo renal excretion 4.

Important Warnings

  • Hypertriglyceridemia risk: Bile acid sequestrants can increase triglycerides; avoid if TG ≥300 mg/dL 6. Monitor triglycerides closely and discontinue if pancreatitis symptoms develop 1
  • GI obstruction: Not recommended in patients with gastroparesis or other GI motility disorders 1
  • Drug interactions: Administer other medications at least 4 hours before colesevelam to prevent absorption interference 1
  • Fat-soluble vitamin deficiencies: May decrease absorption of vitamins A, D, E, and K; supplement at least 4 hours before colesevelam 1

Practical Considerations

Dosing: 3.75 g daily (6 tablets once daily or 3 tablets twice daily with meals, or oral suspension) 2

For your specific patient: The elevated liver enzymes and impaired renal function do not represent absolute contraindications, as colesevelam is non-systemic. However, you must first verify the triglyceride level—if >500 mg/dL, colesevelam is absolutely contraindicated 1. If TG is 300-500 mg/dL, use extreme caution with close monitoring. The hyperchloremia and albuminuria are not relevant to colesevelam prescribing decisions.

Related Questions

What non‑powder alternatives are available for an adult patient who requires a bile‑acid sequestrant instead of cholestyramine powder?
What is Welchol (colesevelam) and its clinical use?
How are bile‑acid sequestrants (cholestyramine, colestipol, colesevelam) indicated, dosed, monitored, and what are their drug interactions and side‑effects when used for LDL‑C lowering?
What are the contraindications to Welchol (colesevelam) tablets?
What are the gastrointestinal implications of taking Colesevelam (bile acid sequestrant) on the stomach?
What step‑by‑step treatment plan should be followed for a patient whose acute cannabis‑induced psychosis has remitted but who now has several months of flat affect and reduced sociability, is currently receiving aripiprazole depot, and requires evaluation for ongoing cannabis use and medication optimization?
What is a concise, literature-supported questionnaire for self-assessment of wound care and skin condition?
Can patients safely perform a basic visual and tactile skin examination themselves rather than relying on medical professionals?
In a patient who recently recovered from an acute cannabis‑induced psychotic episode and is currently on aripiprazole depot but continues to use cannabis, will their flat affect and reduced sociability improve with sustained abstinence?
Is colesevelam appropriate for a patient who is post‑cholecystectomy and post‑colon cancer resection?
What are the clinical features, diagnostic criteria, and recommended treatment for cervicofacial actinomycosis (slowly progressive painless mandibular mass with sulfur‑granule‑containing discharge) and associated canaliculitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.